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Vitamin D Deficiency
An Important, Common, and Easily
Treatable Cardiovascular Risk Factor?
John H. Lee, MD,* James H. O’Keefe, MD,* David Bell, MD,† Donald D. Hensrud, MD, MPH,‡
Michael F. Holick, MD, PHD§
Kansas City, Missouri; Birmingham, Alabama; Rochester, Minnesota; and Boston, Massachusetts
Vitamin D deficiency is a highly prevalent condition, present in approximately 30% to 50% of the general popula-
tion. A growing body of data suggests that low 25-hydroxyvitamin D levels may adversely affect cardiovascular
health. Vitamin D deficiency activates the renin-angiotensin-aldosterone system and can predispose to hyperten-
sion and left ventricular hypertrophy. Additionally, vitamin D deficiency causes an increase in parathyroid hor-
mone, which increases insulin resistance and is associated with diabetes, hypertension, inflammation, and in-
creased cardiovascular risk. Epidemiologic studies have associated low 25-hydroxyvitamin D levels with coronary
risk factors and adverse cardiovascular outcomes. Vitamin D supplementation is simple, safe, and inexpensive.
Large randomized controlled trials are needed to firmly establish the relevance of vitamin D status to cardiovas-
cular health. In the meanwhile, monitoring serum 25-hydroxyvitamin D levels and correction of vitamin D defi-
ciency is indicated for optimization of musculoskeletal and general health. (J Am Coll Cardiol 2008;52:
1949–56) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.050o
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praditionally, vitamin D has been associated primarily with
one health, and it is well understood that vitamin D
eficiency leads to rickets in children and osteomalacia and
steoporosis in adults (1). However, it is now known that
dequate vitamin D status is important for optimal function
f many organs and tissues throughout the body, including
he cardiovascular (CV) system (2). Vitamin D receptors
VDRs) are present on a large variety of cell types, including
yocytes, cardiomyocytes, pancreatic beta-cells, vascular
ndothelial cells, neurons, immune cells, and osteoblasts (1).
itamin D deficiency or insufficiency is prevalent in prac-
ically every segment of the U.S. population, including
hildren and young adults (1). This worldwide pandemic
emains generally unrecognized and untreated.
Evolving data indicate that vitamin D deficiency is
laying an important role in the genesis of coronary risk
actors and CV disease. Vitamin D deficiency seems to
redispose to hypertension, diabetes and the metabolic
yndrome, left ventricular hypertrophy, congestive heart
ailure, and chronic vascular inflammation (1,2). Epidemi-
rom the *Mid America Heart Institute and University of Missouri, Kansas City,
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onsultant for the National Dairy Council and the UV Foundation.m
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ccepted August 13, 2008.logic studies have also recently linked vitamin D deficiency
ith increased risk of major adverse CV events (3). A study
f male health professionals showed a 2-fold risk of myo-
ardial infarction (MI) in subjects who were vitamin D
eficient compared with those in the sufficient range (4).
imilarly, a recent prospective cohort study measured the
itamin D levels in 3,258 German adults who were under-
oing elective cardiac catheterization. During a mean
ollow-up of 7.7 years, individuals in the lowest quartile for
aseline serum 25-hydroxyvitamin D [25(OH)D] had a
isk-adjusted 2-fold increased risk of death, especially CV
eath, compared with those in the highest quartile of
itamin D (5).
This review focuses on the relationship between 2 wide-
pread problems: vitamin D deficiency and CV disease. The
ssues addressed will include: 1) the role of vitamin D
eficiency in the genesis of coronary risk factors and adverse
V events; 2) how repletion of vitamin D stores may
mprove CV health and prognosis; and 3) practical and
pecific recommendations for restoring and maintaining a
ealthy vitamin D status in CV patients, because no
uidelines have been published on this topic yet.
itamin D Basics
itamin D comes in 2 forms: vitamin D2 (ergocalciferol)
nd vitamin D3 (cholecalciferol). Vitamin D2, found in
lants, is the product of ultraviolet B (UVB) (290 to 315
m) irradiation of ergosterol, and can be consumed as
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Vitamin D Deficiency and CV Risk December 9, 2008:1949–56a supplement or in fortified
foods (1). Vitamin D3, a prod-
uct of UVB irradiation of 7-
dehydrocholesterol, is synthe-
sized in the human epidermis or
consumed in the form of oily
fish, fortified foods, or a supple-
ment. Excessive sunlight expo-
sure cannot cause vitamin D tox-
icity because UVB converts
excess vitamin D3 to biologically
inert isomers (1); however, exces-
ive oral vitamin D intake can cause toxicity at very high
oses (6).
Vitamin D is converted in the liver to 25(OH)D, which
s the major circulating metabolite of vitamin D. Serum
5(OH)D concentrations, which reflect both vitamin D
ntake and endogenous production, should be measured to
linically assess vitamin D status (1). In the kidney,
5(OH)D is converted by 1-hydroxylase to its active form,
,25-dihydroxyvitamin D [1,25(OH)2D], which plays a
ital role in maintaining bone and muscle health by regu-
ating calcium metabolism. Although 1,25(OH)2D is the
ctive form of vitamin D, its serum level does not correlate
ith overall vitamin D status and thus is generally not
linically useful (1).
Vitamin D in the form of 1,25(OH)2D is a hormone,
ecause it is produced primarily in 1 organ (the kidney) and
hen circulates throughout the body, where it exerts wide-
anging effects. The VDR is present in most tissues,
ncluding endothelium, vascular smooth muscle, and myo-
ardium (2). In addition, both vascular smooth muscle and
ndothelial cells may have the ability to convert 25(OH)D
o 1,25(OH)2D (7). Circulatory 1,25(OH)2D crosses the
ell membrane and cytoplasm and reaches the nucleus,
here it binds to the VDR. The VDR-bound 1,25(OH)2D
n turn binds to the retinoic acid x-receptor and serves as a
uclear transcription factor, altering gene function and
nducing protein synthesis (1). Directly or indirectly,
,25(OH)2D regulates over 200 genes, including those
nvolved in renin production in the kidney, insulin produc-
ion in the pancreas, release of cytokines from lymphocytes,
roduction of cathelicidin in macrophages, and growth and
roliferation of both vascular smooth muscle cells and
ardiomyocytes (1).
efinition and Prevalence of Vitamin D Deficiency
lthough a consensus regarding the optimal level of serum
5(OH)D has not yet been established, most experts define
itamin D deficiency as a 25(OH)D level of 20 ng/ml (50
mol/l) and vitamin D insufficiency as 21 to 29 ng/ml
Table 1). For all studied end points to date, the optimal
oncentration of 25(OH)D is at least 30 ng/ml (8).
A rapidly evolving knowledge base indicates that vitamin
Abbreviations
and Acronyms
25(OH)D  25-
hydroxyvitamin D
CV  cardiovascular
MI  myocardial infarction
PTH  parathyroid hormone
UVB  ultraviolet B
VDR  vitamin D receptordeficiency is much more prevalent than previously rec-gnized and is present in up to 50% of young adults (9) and
pparently healthy children (1). The Third National Health
nd Nutrition Examination Survey (NHANES III) re-
orted the prevalence of vitamin D deficiency in the U.S. to
e between 25% and 57% of adults (10).
The prevalence of vitamin D deficiency increases in
roportion to distance from the equator because of increased
tmospheric filtering of UVB radiation caused by the
blique angles of the sun’s rays at higher latitudes. Addition-
lly, ethnic groups with darker skin require proportionally more
un exposure to synthesize equivalent amounts of vitamin D
ompared with people with lighter skin coloration (11).
Modern human cultures produce less vitamin D cutane-
usly, in part because of increasingly indoor lifestyles and
fforts to minimize sun exposure by using sunscreens and
ther sun avoidance strategies. Sunscreen with a sun pro-
ection factor of 15 blocks approximately 99% of the
utaneous vitamin D production (12). Additionally, obesity
s associated with vitamin D deficiency (13), probably
ecause of a decreased bioavailability of vitamin D that is
equestered in the fat of individuals with excess adipose
issue (14). After equivalent exposure to UVB radiation or a
olus dose of vitamin D2, obese individuals showed 50%
ower blood levels of vitamins D3 and D2 compared with
onobese individuals, probably because of sequestering of
5(OH)D in adipose tissue (14). Older age also reduces the
apacity for UVB-induced cutaneous synthesis of vitamin
. After equal doses of sunlight exposure, a 70-year-old
erson produces 75% less vitamin D3 than a 20-year-old
erson (15). Other risk factors for vitamin D deficiency are
isted in Table 2.
itamin D Deficiency and CV Disease
pidemiological studies report that the rates of coronary
eart disease, diabetes, and hypertension, like vitamin D
eficiency, increase in proportion to increasing distance
rom the equator (16). Deficient or insufficient serum
5(OH)D levels have been documented in patients with
yocardial infarction (17), stroke (18), heart failure (2),
iabetic CV disease (19), and peripheral arterial disease
20). Recently, the relationship between CV risk factors and
5(OH)D levels was explored among the 15,088 subjects
rom the NHANES III national cohort registry. In this
ross-sectional study, 25(OH)D levels were inversely asso-
iated with hypertension, diabetes mellitus, hypertriglycer-
demia, and obesity (21). Other cross-sectional studies have
itamin D Status
Table 1 Vitamin D Status
Serum 25-Hydroxyvitamin D (ng/ml) Vitamin D Status
10 Severe deficiency
10–20 Deficiency
21–29 Insufficiency
30 Sufficiency150 Toxicity
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December 9, 2008:1949–56 Vitamin D Deficiency and CV Riskonfirmed the links between vitamin D deficiency and both
ypertension and diabetes (22,23). Additionally, vitamin D
eficiency predisposes to insulin resistance, pancreatic beta
ell dysfunction (24), and the metabolic syndrome (24,25).
ne study reported that a daily intake of 800 IU of vitamin
compared with a daily intake of 400 IU of vitamin D
educed the risk of type 2 diabetes by one-third (26). A
tudy of 10,366 Finnish children who were given 2,000 IU
f vitamin D3 per day throughout the first year of life
xperienced a 78% reduced risk of type 1 diabetes over the
nsuing 31 years of follow-up (27). Subsequently, this
nding has been confirmed by a meta-analysis performed on
observational studies by a group in England (28).
A correlation between vitamin D deficiency and sub-
equent major adverse CV events was found among the
,739 Framingham Offspring Study participants who
ere free of CV disease at baseline (3). In this prospective
bservational study, 25(OH)D levels were measured at
aseline and subjects were followed up for a mean of 5.4
ears. The rate of a composite CV end point (fatal or
onfatal MI, ischemia, stroke, or heart failure) was 53%
o 80% higher in people with low vitamin D levels. The
ncreased CV risk associated with vitamin D deficiency
as magnified in the cohort of Framingham offspring
ith hypertension (Figs. 1 and 2).
Vitamin D deficiency predisposes to up-regulation of the
enin-angiotensin-aldosterone system and hypertrophy of
oth the left ventricle and vascular smooth muscle cells (2)
Fig. 3). In vitamin D-deficient animals there is an in-
reased incidence of hypertension, left ventricular hypertro-
hy, and atherosclerosis (29). Human studies indicate that
,25(OH)2D inhibits renin synthesis, which may lower
lood pressure (30). Krause et al. (31) showed that increased
xposure to UVB radiation in a tanning bed 3 times per
eek for 3 months led to a 180% increase in 25(OH)D
evels and a 6-mm Hg reduction in both systolic and
iastolic pressures. A small, randomized, placebo-controlled
tudy of patients with type 2 diabetes and low baseline
5(OH)D levels showed that a single dose of 100,000 IU of
isk Factors for Vitamin D Deficiency
Table 2 Risk Factors for Vitamin D Deficiency
Elderly
Darkly pigmented skin
Institutionalized or homebound
Increased distance from equator
Winter season
Cover-up clothing and/or sunscreen
Air pollution
Smoking
Obesity
Malabsorption
Renal disease
Liver disease
Medications: anticonvulsants, glucocorticoids, antirejection, and human
immunodeficiency virus medicationsitamin D2 reduced systolic blood pressure by a mean of 14m Hg and significantly improved endothelial function as
easured by forearm blood flow (32). In the NHANES III
tudy, the mean systolic blood pressure was about 3 mm Hg
ower in those in the individuals in the highest quintile of
erum 25(OH)D levels compared with those in the lowest
uintile (22).
yperparathyroidism Increases CV Risk
hronic vitamin D deficiency causes secondary hyperpara-
hyroidism, which in turn may mediate many of the detri-
ental CV effects of inadequate vitamin D levels. The
Figure 1 Vitamin D Levels Associated With CVD
Vitamin D deficiency increases CV risk. Kaplan-Meier curves show the probabil-
ity of major adverse CV events in participants with 25(OH)D levels 15 ng/ml
(green lines) and 25(OH)D levels 15 ng/ml (red lines). The increased CV
risk was more apparent in patients with (A) than in patients without (B) hyper-
tension. Reprinted, with permission, from Wang et al. (3). 25(OH)D  25-hy-
droxyvitamin D; CV  cardiovascular; CVD  cardiovascular disease.
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Vitamin D Deficiency and CV Risk December 9, 2008:1949–56hreshold for elevation of parathyroid hormone (PTH) is a
5(OH)D level of 30 ng/ml. Further decreases in serum
5(OH)D levels will result in proportionally higher PTH
evels to maintain serum and total body calcium (Fig. 4).
itamin D deficiency reduces intestinal calcium absorption
y more than 50% (1). The attendant decrease in serum
alcium levels triggers PTH release, which quickly corrects
he calcium level by mobilization of calcium from bone,
ncreased renal tubular calcium reabsorption, and increased
enal production of 1,25(OH)2D.
Figure 2 Hazard Ratio for CVD by Vitamin D Levels
Multivariable adjusted hazard ratios for major adverse
CV events. Data from Wang et al. (3). Abbreviations as in Figure 1.
Figure 3 Potential Mechanisms for CV Toxicity of Vitamin D De
Possible mechanisms of increased cardiovascular (CV) risk from vitamin D deficienThe effects of primary hyperparathyroidism on CV out-
omes were shown in a study that reported approximately
0% lower relative risks of MI, stroke, and death in patients
ho had surgical parathyroidectomy compared with obser-
ation (33). This link between increased PTH and CV
isease was further corroborated by a study of patients with
enal failure and secondary hyperparathyroidism [caused by
ecreased conversion of 25(OH)D to 1,25(OH)2D]. In this
tudy, patients with a PTH level 250 pg/ml had a 2-fold
isk of CV disease compared with those with PTH levels
250 pg/ml (34). Additionally, a recent observational study
ound that elevated PTH levels in elderly individuals was
ssociated with a doubling of mortality during follow-up
ompared with those with normal PTH levels (35).
An increased PTH level is associated with increases in
oth blood pressure (36) and myocardial contractility, which
ventually lead to hypertrophy, apoptosis, and fibrosis of
oth the left ventricle and vascular medial smooth muscle
2). Vitamin D deficiency and/or increased PTH also
redispose to calcification of heart valves, mitral annulus,
nd myocardium, especially in patients with moderate or
evere chronic kidney disease (37).
Chronic kidney disease is associated with markedly in-
reased CV risk (38), which may in part be mediated by
nadequate vitamin D levels. Vitamin D deficiency is asso-
iated with increased mortality rates in the setting of chronic
idney disease (39), and repleting vitamin D in such
atients improves outcomes. Recent observational studies of
atients with chronic kidney disease and hyperparathyroid-
sm found that the oral administration of 1,25(OH)2D3
ncy
H  parathyroid hormone; RAAS  renin-angiotensin-aldosterone system.ficie
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December 9, 2008:1949–56 Vitamin D Deficiency and CV Riskalso known as activated vitamin D or calcitriol) was
ssociated with significantly improved survival (40). A
lacebo-controlled study of 30 pre-dialysis renal failure
atients with secondary hyperparathyroidism showed that
reatment with 1,25(OH)2D3 improved left ventricular
iastolic function (41). Vitamin D analogs used in patients
n dialysis have been shown to improve survival at all doses
ested thus far (42).
Low 25(OH)D levels and increased PTH levels increase
oth inflammation and the risk of adverse CV events
36). Vitamin D deficiency increases systemic inflamma-
ion, as documented by elevated levels of C-reactive protein
nd interleukin-10 (2). Furthermore, administration of
,25(OH)2D to vitamin D-deficient individuals down-
egulated inflammatory markers (C-reactive protein, and so
n) and conferred an antiproliferative effect (43). Extrarenal
ynthesis of 1,25(OH)2D occurs through cytokine stimula-
ion (7) and is locally important in the paracrine regulation
f cellular growth, differentiation, and function (44). This
ay explain why vitamin D deficiency has been associated
ith type 1 diabetes, cancer, and multiple sclerosis (45).
utcome Studies
recent meta-analysis of 18 randomized controlled trials
omprising 57,000 individuals showed that a vitamin D
ntake500 IU/day improved all-cause mortality, in part by
ecreasing CV deaths (46). Moreover, the data regarding
oth efficacy and CV safety for vitamin D appear to be
uperior to that for calcium supplements. Indeed, calcium
upplementation has recently been implicated as possibly
Figure 4 Relationship of Serum Levels
of Parathyroid Hormone and Vitamin D
The inverse relationship between serum 25-hydroxyvitamin D levels and serum
parathyroid hormone levels. Reprinted, with permission, from Zittermann et al. (2).ncreasing the risk of adverse CV events, particularly in Datients with chronic kidney disease (47,48). Calcium sup-
lements acutely increase serum calcium levels, which might
ccelerate arterial calcification (49). In contrast, serum
itamin D levels are inversely associated with coronary
rtery calcification (50).
Osteoporosis and atherosclerotic CV disease share many
ommon risk factors, and a pathologic link between these 2
ighly prevalent age-related diseases has been suggested
51). A large number of middle-aged to elderly individuals
t risk for both CV disease and osteoporosis may benefit
rom therapies that are likely to improve both conditions,
uch as an anti-inflammatory diet, daily exercise (especially
eight-bearing forms), avoidance of both tobacco and heavy
lcohol intake, and possibly vitamin D supplementation.
itamin D and Myopathy
yalgias are generally the first manifestation of vitamin D
eficiency. Severe vitamin D deficiency with corresponding
levations of PTH were reported in 88% of women who
resented with muscle pains and weakness (52). Another
tudy investigated 150 patients with nonspecific musculo-
keletal pains and reported that 25(OH)D levels were
nsufficient in 93% of individuals and severely deficient in
8% (53). A meta-analysis of 5 randomized clinical trials
eported that vitamin D supplementation reduced the risk
f falls, most likely from improved muscle function and
trength (54). Myalgia, the most common complaint re-
orted by patients on statin therapy, may be at least in part
aused by underlying vitamin D deficiency. Anecdotally, we
ave observed that repletion of 25(OH)D levels predictably
mproves or resolves statin-related myalgias.
upplementing Vitamin D
raditionally, up to 95% of the body’s vitamin D require-
ent comes from the synthesis in the epidermis on sun
xposure, with the remainder ingested from dietary sources
Table 3) (55). The U.S. government’s current recommen-
ation for oral vitamin D is 200 IU daily for individuals age
50 years, 400 IU daily for individuals between age 50 and
0 years, and 600 IU for those older than age 70 years.
tudies indicate that the average U.S. adult consumes about
30 IU vitamin D per day (56). However, it has been
elected Food Sources of Vitamin D
Table 3 Selected Food Sources of Vitamin D
Food IU per Serving
Cod liver oil, 1 tablespoon 1,360
Wild-caught salmon, 3 oz 600–1,000
Farmed salmon, 3 oz 100–250
Mackerel, cooked, 3 oz 345
Tuna fish, canned in oil, 3 oz 200
Sardines (with bones), canned in oil, drained, 1 oz 250
Milk, nonfat, reduced fat, and whole,
vitamin D-fortified, 1 cup
98ata from Holick (1) and the National Institutes of Health (55).
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Vitamin D Deficiency and CV Risk December 9, 2008:1949–56stimated that 1,000 to 2,000 IU is necessary to satisfy the
ody’s needs for most people (8). Many experts in the field
uggest the recommended daily intake of vitamin D be
ncreased to at least 800 to 2,000 IU of vitamin D daily,
oses that are difficult to achieve without supplementation,
articularly in higher latitudes and in areas of extreme
inter climate. A dose of vitamin D3 up to 2,000 IU daily
as been deemed by the U.S. Food and Drug Administra-
ion’s nutritional guidelines to be generally recognized as
afe. A recent review concluded that the safe upper limit for
itamin D consumption is 10,000 IU per day (57); doses
Figure 5 Response of Serum
Vitamin D Levels to Supplementation
Effect of dose and duration of vitamin D supplementation on the mean
serum 25-hydroxyvitamin D [25(OH)D] concentration achieved. Data from Vieth
et al. (62).
Figure 6 Treatment Recommendations for Vitamin D Deficiency
25(OH)D  25-hydroxyvitamin D.bove this increase risk of renal calculi formation, especially
n patients with absorptive hypercalcuria and end-stage
enal disease patients on dialysis (58).
A study of 340 children ages 10 to 17 years found that
ncreasing the intake of oral vitamin D 10-fold, from the
urrently recommended dose of 200 to 2,000 IU daily, was
equired to reach a 25(OH)D level of 30 ng/ml (the lower
nd of the optimal range) (59). The investigators concluded
hat doses equivalent to 2,000 IU of vitamin D3 daily were
ot only safe for adolescents, but also necessary for achiev-
ng the desirable vitamin D levels.
The most potent sources of vitamin D are sunlight (about
,000 IU vitamin D3 per 5 to 10 min of mid-day, midyear
xposure of arms and legs for a light-skinned Caucasian) or
rescription oral supplements of 50,000 IU capsule of either
itamin D2 or D3 every 2 weeks (1). Among foods, oily fish
ave the highest content of vitamin D3, which ranges from
00 to 1,000 IU per 3.5 oz (1,60), whereas other sources
uch as milk or orange juice fortified with vitamin D contain
p to 100 IU per serving.
As a general rule, every 100 IU vitamin D ingested daily
ncreases the 25(OH)D level by about 1 ng/ml (61,62) (Fig.
). Over-the-counter dietary supplements of vitamin D2
nd D3 typically contain 400 to 5,000 IU per capsule. Oral
upplementation with either vitamin D2 or D3 initially will
ncrease vitamin D levels equally well (63), although the
ncreases in serum 25(OH)D levels seem to persist longer
fter a bolus dose of vitamin D3 than D2 (64).
Treatment of vitamin D-deficient individuals should be
nitiated with 50,000 IU of vitamin D2 or D3 weekly for a
eriod of 8 to 12 weeks. Once the initial repletion phase is
omplete, maintenance therapy can be continued in 1 of 3
ays: 1) 50,000 IU vitamin D2 or D3 every 2 weeks; 2)
1
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December 9, 2008:1949–56 Vitamin D Deficiency and CV Risk,000 to 2,000 IU vitamin D3 daily; and 3) sunlight
xposure for 5 to 10 min for Caucasians (longer times
equired for people with increased skin pigmentation) be-
ween the hours of 10 AM to 3 PM (spring, summer, and fall)
1,61) (Fig. 6).
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